INTRODUCTION
Malignant melanoma is an aggressive tumor derived from melanocytes and is mostly resistant to current therapeutic approaches. Some details are known about the processes leading to the development of malignant melanoma, but the molecular cause of the disease remains unknown. We speculated that c-Jun (a member of the AP-1 transcription factor family) is a key molecule in melanoma development. [1] [2] [3] Recent studies have shown that c-Jun is activated by a novel pathway that exists in melanoma in addition to the Ras/Raf/MEK/ERK pathway and PI3K/ AKT signaling. 4 The constitutive activity of the AP-1 transcription factor family influences the expression of a variety of regulators of cell proliferation, migration and survival, which are significantly involved in melanoma development and metastasis. 5, 6 Inhibiting the transcription factor c-Jun could represent a therapeutic approach against melanoma. In this study, we screened for possible miRNAs targeting the transcription factor c-Jun. miRNAs are small non-coding RNA molecules that regulate gene expression on the post-transcriptional level. [7] [8] [9] Recent research has not only revealed their strong impact on almost every regulatory pathway in eukaryotic cells but has also clearly demonstrated their involvement in the tumorigenesis of a variety of human cancers. [10] [11] [12] [13] Studies from our own group as well as from several other groups revealed that the expression of many miRNAs is deregulated in malignant melanoma cells and that deregulated miRNA expression is undoubtedly linked to important processes affecting melanoma formation and progression. [14] [15] [16] miRNAs are incorporated into the RNA-induced silencing complex (RISC) where they directly bind to a member of the Argonaute (Ago) protein family. 17 miRNAs guide RISC to complementary target sites on mRNAs and modulate mRNA stability by inducing degradation of the mRNA 18 or controlling translation. 8, 9, 19 Most of the miRNA target sites that have been characterized thus far are located in the 3 0 -untranslated region (UTR) of mRNAs. However, miRNAs have also been demonstrated to regulate gene expression by interacting with the 5 0 -UTR or the coding region of target mRNAs. 20, 21 The induction of cancer by aberrant expression of or mutations in miRNA genes indicates that miRNAs function as oncogenes or tumor suppressors. 22 Some miRNAs are already known to have an important role by targeting specific genes in malignant melanoma. 16, 23, 24 Because of the loss of miR-125b and the increased amount of c-Jun in malignant melanoma, we were interested in determining whether miR-125b is the post-transcriptional regulator of c-Jun protein.
RESULTS
In previous studies, we determined that c-Jun is regulated at the post-transcriptional level in melanoma. 4 We revealed that regulation via the 3 0 -and 5 0 -UTRs, mRNA degradation and modification of the protein are not the main modulating events for post-transcriptional regulation of this molecule. As miRNA regulation is not restricted to the 3 0 -UTR and functional target sites have also been found in the coding sequence, we hypothesized that c-Jun protein levels might be modulated by miRNAs. 8, 9, 19 By careful analysis using the program miRWalk (http://www.umm.uniheidelberg.de/apps/zmf/mirwalk/index.html), we determined a seed sequence for miR-125b (901 bp 3 0 of ATG, CTCAGGGA) and two seed sequences for miR-527 (324 and 336 bp 3 0 of ATG, GAGGGCTTCG) in the coding region of c-Jun mRNA. Of these, only the expression of miR-125b was found to be deregulated in melanocytes compared with melanoma cells in an miRNA array (Agilent) analysis previously published by our group. 14 In addition, quantitative real-time PCR (qRT-PCR)-based comparative analysis of miR-527 expression in melanoma cell lines and melanocytes revealed no difference and a general low expression of miR-527 (data not shown). Therefore, miR-527 was not analyzed further. After determining the expression levels of miR-125b in normal human epidermal melanocytes (NHEMs) and six melanoma cell lines (Mel Im, Mel Juso, Mel Ju, A375, 1205 Lu and HMB2), we found the expression of this miRNA to be strongly downregulated in the melanoma cell lines (by 495%) compared with NHEM ( Figure 1a) . In tissue samples from either primary melanoma (PT) or melanoma metastasis (MET), significant downregulation of miR125b expression compared with NHEM was confirmed (Figure 1b) . Further, in-situ hybridization of melanoma tissues revealed reduced expression of miR-125b compared with normal skin (dark blue staining). The negative control showed no blue staining ( Figure 1c ). In summary, we found that miR-125b is deregulated in melanoma cells and tissues compared with normal melanocytes.
To determine the importance of this reduction of miR-125b in melanoma, we treated Mel Im and Mel Juso melanoma cells with pre-miR-125b and analyzed their proliferative and migratory potential. Re-expression of miR-125b resulted in a significant reduction of proliferation ( Figure 2a ) and migration ( Figure 2b ) in both cell lines, suggesting that exogenous miR-125b expression has a tumor suppressive function in melanoma. mRNA analysis of pre-miR-125b-transfected cells by qRT-PCR revealed the regulation of c-Jun target gene such as MMP9 (Figure 2c ), demonstrating the functional importance of the loss of miR-125b in malignant melanoma.
Due to the potential binding of miR-125b to the c-Jun mRNA (Figure 3a) , we aimed to determine whether miR-125b can regulate c-Jun translation. Western blot analysis to detect c-Jun after the transfection of pre-miR-125b into three melanoma cell lines (Mel Im, Mel Juso and Mel Ju) revealed strong downregulation of c-Jun protein (Figure 3bi and ii). Pre-miR-transfected melanoma cell lines achieved physiologically relevant levels of miR-125b (Figure 3biii ) comparable to NHEMs (Figure 1a) . Interestingly, no regulation of c-Jun mRNA expression by miR-125b was observed (Figure 3c ). In-situ hybridization of melanoma tissues revealed reduced expression of miR-125b compared with a high (dark blue) miR-125b level in the normal epidermis. This result correlates to the increased expression of c-Jun protein in melanoma tissues and decreased c-Jun protein in the corresponding normal epidermis, as detected by immunohistochemistry ( Figure 3d ).
We further confirmed regulation of c-Jun expression by miR125b using a cellular model system of the parental melanoma cell line HMB2. Here, the so-called HMB2-5 cell clone resembles melanocytic cells, showing a more differentiated phenotype. HMB2-5 cells lack protein expression of melanoma inhibitory activity (MIA) and c-Jun, which are functionally important in malignant melanoma. 25 Analysis of miR-125b and c-Jun (Figure 4ai and ii).
Next, we were interested in determining whether there was a direct interaction/binding between miR-125b and the coding region of c-Jun. Mutations of the seed sequence in the coding region of c-Jun should lead to a decreased binding of miR-125b compared with the wild-type (wt) seed sequence. Therefore, we mutated the seed sequence CTCAGGGA to CTGCGAGA in a HAtagged c-Jun expression vector, which should result in a complete loss of repression by miR-125b. Exogenous expression of HAtagged wt c-Jun (HAJun) in the HMB2-5 cell clone (expressing miR125b) did not lead to c-Jun protein expression, whereas the mutated version (HAJun Mut miR-125b) led to strong induction of protein expression in this cell type (Figure 4b ). mRNA analysis showed no differences in c-Jun mRNA expression between HaJun or HAJun Mut miR-125b transfection (data not shown).
We further performed EMSA experiments to investigate the consequences of the exogenous expression of HAJun and HAJun Mut miR-125b on AP-1-DNA binding in HMB2-5. In agreement with the western blot data, strong induction of direct AP-1-DNA binding could be detected by transfecting HAJun Mut miR-125b but not by transfecting HAJun, which contains a functional miR125b seed sequence ( Figure 4c ). We further analyzed NHEM in EMSA experiments and used the converse approach. Treatment with anti-miR-125b to inhibit miR-125b activity in NHEM cells resulted in an increased AP-1-DNA binding capability ( Figure 4d ).
To further prove direct binding of miR-125b to c-Jun mRNA, we aimed to determine whether c-Jun mRNA can be found in the RISC in melanoma cells after miR-125b transfection. We transfected Mel Im and Mel Juso melanoma cells, with either pre-miR125b or a control pre-miR and immunoprecipitated the RISC using an anti-Ago-2 antibody. The mRNA attached to the complex was analyzed by qRT-PCR for c-Jun, and we determined that there was strongly enhanced binding of c-Jun mRNA to the RISC (Figure 5ai ). This result could be confirmed by analyzing the PCR products by gel electrophoresis (Figure 5aii ). MIA served as a control without a binding site for miR-125b and with strong expression in melanoma cells.
To further demonstrate the direct binding of miR-125b in the coding sequence and the effects of miR-125b binding in this region, the luciferase coding sequence in a pGL3 plasmid was mutated, generating a classical miR-125b seed sequence ( Figure 5b ). Reporter gene assays with the HMB2 model system revealed that an increase in miR-125b activity results in a decrease in luciferase gene expression ( Figure 5c ). Consequently, we showed that miR-125b is able to post-transcriptionally regulate its specific target genes by binding in the coding region.
DISCUSSION
Malignant melanoma is an aggressive tumor with a disposition to early metastasis and is mostly resistant to current therapeutic approaches. [26] [27] [28] Aberrant expression patterns of certain miRNAs could also contribute to the initiation and progression of melanoma. 22, 23, 29 Several miRNAs are already known to act as so-called oncomirs (miRNA species with either oncogenic or tumor-suppressing functions). miRNAs are known to control cell proliferation, differentiation and metabolism through their specific gene regulatory network. Hundreds of genes are thought to be regulated by one single miRNA, and at least one-third of human protein-coding genes are targets of miRNAs. 23, 24, 30 Calin et al. 31 postulated that miR-125b is a main regulator in breast, lung, ovarian and cervical cancers. However, miRNAregulated processes are currently poorly understood and little is known about the possible regulatory potential of miR-125b in malignant melanoma. We showed for the first time that the proliferative and migratory potential of melanoma cells is influenced by miR-125b. These findings indicate that this miRNA has an important role in malignant melanoma. We determined that miR-125b is downregulated in melanoma cells and tissues (primary melanoma and metastases) compared with primary human melanocytes (NHEMs), which are commonly used as calibrators for melanoma studies. The downregulation of miR-125b in cutaneous malignant melanoma cells and its influence on cell survival and senescence has been confirmed by further studies. 32, 33 Moreover, some miR125b-regulated genes in malignant melanoma are already known, for example, Akt3, Bcl-2 and E2F2. 32 These findings suggest that miR-125b is a potential tumor suppressor in malignant melanoma.
Previous studies have already shown that the transcription factor family AP-1 has an important role in tumor development and progression, and thus, the members of this family could be 1 Data from our group confirmed that c-Jun is the main regulator of AP-1 activity in malignant melanoma. 4, 36 Moreover, it is already well known that c-Jun is regulated on the post-transcriptional level. 4 Targeting transcription factors could be one mechanism by which miRNAs regulate multiple target genes, as described in previous studies. 30, 37 However, no transcription factors are known to be regulated by miR-125b. Therefore, we were interested in determining whether a correlation existed between the miR-125b expression pattern and the expression and activation of the transcription factor c-Jun. We were able to determine that miR125b can bind within the coding sequence (CDS) of c-Jun mRNA and thus regulate c-Jun protein expression, activity and AP-1 binding to DNA to regulate its specific target genes. 4, 36 miRNAs are a class of non-coding RNAs that are able to regulate gene expression by targeting protein encoding RNAs. Most of these miRNAs are known to regulate gene expression through imperfect or perfect base pairing with the 3 0 -UTR of targeted mRNA, resulting in translational repression by mRNA destabilization and degradation. 38 Several other studies have described miRNA binding sites in the 5 0 -UTR of mRNAs. 20 Little is known about the post-transcriptional regulatory potential and mechanisms of miRNAs in cancer, and little is known about the mechanism by which binding to the CDS of the target mRNA exerts a regulatory effect. We discovered a new translational regulatory mechanism by which miRNAs bind to the CDS of the target mRNA. The already described influence of miR-125b in apoptosis and senescence of melanoma cells 33 could possibly also be an effect of the regulation of c-Jun by miR-125b in melanoma. 39 In addition, c-Jun can positively regulate cell proliferation through the repression of tumor suppressor gene expression and function and the induction of cyclin D1 transcription. Our results echo this proliferative effect and suggest that c-Jun could be the key functional molecule mediating the effects of miR-125b.
Taken together, the results in this work demonstrated that the transcription factor c-Jun is regulated via miR-125b in melanoma, thereby indirectly regulating c-Jun target genes. This target genes include a wide set of substrates controlling the cell cycle as well as cell proliferation and differentiation. Thus, we identified a novel regulatory mechanism of c-Jun by miR-125b binding to the CDS of c-Jun. This finding adds new information on the role of deregulated c-Jun gene expression in malignant melanoma. Ongoing analyses of the cause of miR-125b loss in melanoma cells could lead to insights into the fundamental processes of melanoma development and progression. Analyzing the expression patterns of miRNAs in malignant melanoma and investigating the specific target genes could lead to robust biomarkers as well as attractive therapeutic targets.
MATERIALS AND METHODS

Cell culture and tissue samples
Melanoma cell lines Mel Juso, Mel Im, Mel Ju, A375, 1205 Lu, HMB2 and NHEMs were described previously. 40, 41 Cell lines Mel Juso and A375 were derived from primary cutaneous melanomas; Mel Im, Mel Ju, 1205 Lu and HMB2 were derived from metastases of malignant melanomas. Cells were maintained in DMEM supplemented with penicillin (400 units/ml), streptomycin (50 mg/ml), L-glutamine (300 mg/ml), 10% FCS (SigmaAldrich, Steinheim, Germany) and split at a 1:5 ratio every 3 days. NHEMs (PromoCell, Heidelberg, Germany) were derived from neonatal skin. Isolation and cultivation of NHEMs were described previously. 4 Cells were used between passages 2 and 4 and not later than 2 days after trypsinization. HMB2-5 is a cell clone resembling melanocytes generated in our laboratory. Once a week this cell line is treated with geneticin (2 mg/ml) to ensure selection.
Tissue Combined miRNA/total RNA isolation and reverse transcription Enriched small RNA species containing miRNAs and total cellular RNA were isolated from cultured cells using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA). Snap-frozen samples from primary tumors and melanoma metastases were first disrupted in Ambions mirVana miRNA Isolation Kit lysis buffer by using tubes containing 1.4 mm ceramic beads (Peqlab, Erlangen, Germany) and a Precellys24 lyser/homogeniser (Bertin Technologies, Montigny-le-Bretonneux, France). miRNAs were reverse transcribed using the RT reaction set-up of an mirVana qRT-PCR miRNA Detection Kit together with mirVana RT primers specific for hsa-miR-125b and 5S rRNA (Ambion), respectively. cDNAs of total RNA fractions were generated using SuperScript II Reverse Transcriptase Kit (Invitrogen, Groningen, The Netherlands).
Analysis of gene and miR-125b expression by quantitative PCR
qRT-PCR was performed on a Lightcycler (Roche, Mannheim, Germany). cDNA template (500 ng), 0.5 ml (20 mM) of forward and reverse primers and 10 ml of Sybr Premix Ex Taq (TaKaRa, Shiga, Japan) in a total of 20 ml were applied to the following PCR program: 30 s 95 1C (initial denaturation); Annealing and melting temperatures were optimized for each primer set (Table 1) . b-Actin was used for normalization.
qRT-PCR of reverse-transcribed miRNAs was performed as described.
14 Briefly, cDNA template (500 ng), 1 ml (20 mM) miRNA-specific PCR primers (Ambion) and 10 ml of Sybr Premix Ex Taq (TaKaRa) were added in a total of 20 ml. The following PCR program was used for hsa-miR-125b amplification: In-situ hybridization for miR-125b detection
Locked nucleic acid in-situ hybridization analysis was performed on paraffin-embedded melanoma and normal human skin tissue samples with LNA probes for the miR-125b (Exiqon, Vedbaek, Denmark). The miRNA hybridization on formalin-fixed paraffin-embedded tissue samples was performed following the instructions of the miRCURY LNA microRNA ISH miR-125b controls c-Jun in malignant melanoma M Kappelmann et al Optimization Kit (FFPE) (Exiqon). LNA probe for the miR-125b was used and a negative control (scrambled LNA probe) was also assembled.
Mutation of the miR-125b target sequences in c-Jun
The human c-Jun expression vector (HA-tagged c-Jun) 42 was used for the mutagenesis study. To destroy the miR-125b target sequence in the coding region of c-Jun, three nucleotides of the seed sequence were exchanged using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to manufactures' instructions. Therefore, the primers Mut_miR-125b forward and reverse were used. DNA sequencing was performed to assure correctness of the sequences cloned (Entelechon, Regensburg, Germany).
Mutation of the pGL 3 promotor luciferase gene
To create an miR-125b binding site in the luciferase gene of the pGL 3 promoter plasmid ('pGL3 plasmid'; accession number http:// www.ncbi.nlm.nih.gov/nuccore/U47298), nucleotides were exchanged using a QuikChange site-directed mutagenesis kit (Stratagene) as mentioned above. Therefore, the primers Mut-primer pGL 3 _miR-125b (wt) forward and reverse (Table 1) were used.
Transfecting cells with pre-miRs and anti-miRs
In all, 2 Â 10 4 cells were seeded each well in six-well plates. Transfection of melanoma cell lines was performed with HiPerFect transfection reagent (Qiagen). In all, 5.4 ml of 20 mM pre-miR and anti-miR stocks (Ambion), respectively, were transfected using 18 ml HiPerFect transfection reagent per well. Ambions anti-miR negative Control #1 and Pre-miR negative Control #1 served as negative controls. Total RNA was isolated 24 h after transfection using E.Z.N.A. Micro Elute Total RNA Kit (Omega, Norcross, GA, USA) and protein was isolated using RIPA lysis buffer (Roche) following manufactures' instructions. It is to mention that Ambions' pre-miR molecules are actually molecules similar to siRNAs mimicking the mature miRNA rather than a real miRNA precursor molecule. We therefore refer to the molecules as pre-miRs in the text to indicate the nature of the molecules distributed by Ambion.
NHEMs were transfected using HiPerFect transfection reagent (Qiagen) as described above. Total RNA and protein were isolated 24 h after transfection using the same protocols as mentioned above.
Transfection and luciferase assay
In all, 2 Â 10 4 cells were seeded each well in six-well plates and transfected with 0.5 mg of reporter constructs using Lipofectamine Plus (Invitrogen). For co-transfection experiments, in addition to the reporter constructs, 0.5 mg of expression plasmid or related empty vector was transfected. Twenty-four hours after transfection, the cells were lysed with Passive Lysis Buffer 1x (Promega, Mannheim, Germany) and luciferase activity was determined. To normalize transfection efficiency, 0.2 mg of a pRL-TK plasmid (Promega) was co-transfected in each sample reaction and Renilla luciferase activity was measured by a luminometric assay (Dual-Luciferase Reporter Assay; Promega).
Western blotting
In all, 3 Â 10 6 cells were resuspended in 200 ml RIPA buffer (Roche) and lysed for 15 min at 4 1C. Insoluble fragments were removed by centrifugation at 13 000 r.p.m. for 10 min and the supernatant was stored at À 20 1C. In total, 40 mg of RIPA complete cell lysates was loaded per lane and separated on SDS-PAGE gels (Invitrogen) and subsequently blotted onto a PVDF membrane. After blocking for 1 h with 3% BSA/PBS in case of anti-cJun and 5% non-fat dry milk/TBS-T in case of anti-HA tag, the membrane was incubated for 16 h with one of the following antibodies: anti-c-Jun (1 in 1000 dilution; Upstate, Merck, Darmstadt, Germany), anti-b-actin (1 in 5000 dilution; Sigma-Aldrich) and anti-HA tag (1 in 1000 dilution; Cell Signaling, Frankfurt am Main, Germany). After three washing steps with TBS-T, the membrane was incubated for 1 h with an alkaline phosphatecoupled secondary anti-mouse (1 in 3000 dilution in TBS-T) or anti-rabbit (1 in 3000 dilution in TBS-T) IgG antibody (Chemicon, Hofheim, Germany) and then washed again for three times in TBS-T. Finally, immunoreactions were visualized by NBT/BCIP (Sigma-Aldrich) staining.
Boyden chamber migration assay
Migration assays were performed in Boyden chambers containing polycarbonate filters with 8 mm pore size (Costar, Bodenheim, Germany), essentially as described previously. 43 Filters were coated with gelatin (5 mg/L). The lower compartment was filled with fibroblast-conditioned medium, used as a chemoattractant. In all, 3 Â 10 4 cells were seeded each chamber and incubated at 37 1C for 4 h. Afterwards, the filters were collected and the cells adhering to the lower surface were fixed, stained and counted as described previously. 44 Cell proliferation kit II (XTT) Cells were seeded as monolayer cultures in 100 ml cultivation medium without phenol red in a 96-well plate (Corning Inc., Corning, NY, USA) at a density of 1 Â 10 4 and 2 Â 10 4 cells per well and incubated in humidified atmosphere containing 5% CO 2 at 37 1C for the indicated time period. Experiments were performed in triplicates as described previously. 45 After 1, 2, 3 and 4 days of incubation, 50 ml of XTT labeling and electron-coupling reagent (Roche) was added to the respective well, and plates were incubated at 37 1C. Absorbance was measured after 2 and 4 h of incubation at 450 nm against a reference wavelength at 650 nm using a microplate reader (Emax precision microplate reader; Molecular Devices, Sunnyvale, CA, USA).
Ago-2 co-immunoprecipitation
Protein-G-sepharose beads (GE Healthcare, Munich, Germany) were rinsed four times with ice-cold PBS (used in all subsequent washing steps), and incubated with monoclonal anti-Ago-2 overnight at 4 1C. Beads were then washed four times with PBS. Twenty-four hours after miR-125b or miRcontrol transfection, the Mel Im or Mel Juso cells (3 Â 10 6 ) were lysed in 100 ml RIPA buffer (Roche) and incubated for 15 min at 4 1C. Insoluble fragments were removed by centrifugation at 13 000 r.p.m. for 10 min and the supernatant was stored at À 20 1C. In all, 100 mg protein lysate was diluted in PBS to a total volume of 300 ml. The lysate was incubated with Protein-G-sepharose beads at 4 1C for 3 h. After co-immunoprecipitation, the beads were washed four times with ice-cold PBS. RNAs that coimmunoprecipitated with anti-Ago-2 antibodies were extracted using RNeasy kit (Qiagen) as described previously. 44 cDNAs were generated by reverse transcriptase reaction performed in 20 ml reaction volume containing B5 ng of co-immunoprecipitated RNA. MIA served as a negative control.
Expression analysis after Ago-2 co-immunoprecipitation
Reverse transcription PCR (RT-PCR) analysis of c-Jun and MIA was done using specific primers ( Table 1 ). The PCR was done in a 20-ml reaction volume containing 5 ng cDNA, 0.5 ml (20 mM) of forward and reverse primers and 10 ml of Sybr Premix Ex Taq (TaKaRa) in a total of 20 ml were applied to the following PCR program: 30 s 95 1C (initial denaturation); 20 1C/s temperature transition rate up to 95 1C for 15, 10 s 60 1C annealing, 20 s 72 1C, 10 s acquisition mode single, repeated for 35 times (amplification). The reaction was stopped and the PCR products were resolved on 1.5% agarose gels.
Statistical analysis
In the bar graphs, results are expressed as mean ± s.d. (range) or percent. Comparison between groups was made using the Student's unpaired ttest. A P-value of o0.05 was considered as statistically significant (NS: not significant, *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001). All calculations were performed using the GraphPad Prism Software (GraphPad Software, Inc., San Diego, CA, USA).
